Miner Company
Carl Zeiss Meditec: Hitting The Bottom
Carl Zeiss Meditec is rated a 'Strong Buy' with a €75/share price target, reflecting significant undervaluation after a 60% share price decline. CZMWF's challenges stem from Chinese market weakness, unfavorable product mix, and FX headwinds, but core operational expenses remain stable, and non-China APAC trends are positive. Despite near-term uncertainty and no guidance, I see minimal bankruptcy risk, and strong market positioning, and I expect AEPS to reach €2.4/share by 2028-2029.
Carl Zeiss Meditec is rated a 'Strong Buy' with a €75/share price target, reflecting significant undervaluation after a 60% share price decline. CZMWF's challenges stem from Chinese market weakness, unfavorable product mix, and FX headwinds, but core operational expenses remain stable, and non-China APAC trends are positive. Despite near-term uncertainty and no guidance, I see minimal bankruptcy risk, and strong market positioning, and I expect AEPS to reach €2.4/share by 2028-2029.